ATE523512T1 - Nalmefen-prodrugs - Google Patents

Nalmefen-prodrugs

Info

Publication number: ATE523512T1
Authority: AT; Austria
Prior art keywords: prodrugs; nalmefen; compounds; disorders; alcohol
Prior art date: 2008-04-24

Application number

AT09733923T

Other languages

English (en)

Inventor

Michel Guillaume

Tim Gaekens

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-24

Filing date

2009-04-23

Publication date

2011-09-15

2009-04-23 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2011-09-15 Application granted granted Critical

2011-09-15 Publication of ATE523512T1 publication Critical patent/ATE523512T1/de

Links

239000000651 prodrug Substances 0.000 title abstract 2
229940002612 prodrug Drugs 0.000 title abstract 2
208000007848 Alcoholism Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
206010012335 Dependence Diseases 0.000 abstract 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
208000001613 Gambling Diseases 0.000 abstract 1
208000030990 Impulse-control disease Diseases 0.000 abstract 1
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 1
206010034158 Pathological gambling Diseases 0.000 abstract 1
206010001584 alcohol abuse Diseases 0.000 abstract 1
201000007930 alcohol dependence Diseases 0.000 abstract 1
208000025746 alcohol use disease Diseases 0.000 abstract 1
238000001311 chemical methods and process Methods 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229960005297 nalmefene Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT09733923T 2008-04-24 2009-04-23 Nalmefen-prodrugs ATE523512T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08155094		2008-04-24
PCT/EP2009/054882 WO2009130272A1 (en)	2008-04-24	2009-04-23	Nalmefene prodrugs

Publications (1)

Publication Number	Publication Date
ATE523512T1 true ATE523512T1 (de)	2011-09-15

Family

ID=39816976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09733923T ATE523512T1 (de)	2008-04-24	2009-04-23	Nalmefen-prodrugs

Country Status (19)

Country	Link
US (1)	US8440686B2 (de)
EP (1)	EP2291380B1 (de)
JP (1)	JP6009764B2 (de)
KR (1)	KR101598137B1 (de)
CN (1)	CN102066381A (de)
AT (1)	ATE523512T1 (de)
AU (1)	AU2009239929B2 (de)
CA (1)	CA2722246C (de)
CY (1)	CY1112295T1 (de)
DK (1)	DK2291380T3 (de)
ES (1)	ES2373364T3 (de)
HR (1)	HRP20110824T1 (de)
ME (1)	ME01319B (de)
PL (1)	PL2291380T3 (de)
PT (1)	PT2291380E (de)
RS (1)	RS52041B (de)
RU (1)	RU2495042C2 (de)
SI (1)	SI2291380T1 (de)
WO (1)	WO2009130272A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3703694A4 (de)	2017-11-03	2021-08-18	Nirsum Laboratories, Inc.	Opioidrezeptorantagonist-prodrugs
TW202015684A (zh) *	2018-06-21	2020-05-01	景凱生物科技股份有限公司	那曲酮、納美芬及其衍生物之前藥
WO2020223894A1 (en) *	2019-05-07	2020-11-12	Nirsum Laboratories, Inc.	Opioid receptor antagonist prodrugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4673679A (en) *	1986-05-14	1987-06-16	E. I. Du Pont De Nemours And Company	Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US5086058A (en) *	1990-06-04	1992-02-04	Alko Ltd.	Method for treating alcoholism with nalmefene
DE69427551T2 (de)	1993-03-15	2002-05-16	National Science Council, Taipeh/T'ai-Pei	Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
JPH06271578A (ja) *	1993-03-15	1994-09-27	Natl Sci Council	鎮痛剤ナルブフィン前薬の誘導体
US5869669A (en) *	1996-07-26	1999-02-09	Penick Corporation	Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
EP1423116A1 (de) *	2001-08-14	2004-06-02	Biotie Therapies Corp.	Verfahren zur behandlung von alkoholismus oder alkoholmissbrauch
US20040033253A1 (en) *	2002-02-19	2004-02-19	Ihor Shevchuk	Acyl opioid antagonists
WO2005009377A2 (en) *	2003-07-23	2005-02-03	University Of Kentucky Research Foundation	Novel oral bioavailable prodrugs
WO2008101187A2 (en) *	2007-02-16	2008-08-21	Pharmacofore, Inc.	Pro-drugs of peripheral phenolic opioid antagonists
US20110053971A1 (en) *	2008-04-24	2011-03-03	Janssen Pharmaceutica Nv	Nalmefene di-ester prodrugs

2009
- 2009-04-23 EP EP09733923A patent/EP2291380B1/de active Active
- 2009-04-23 PT PT09733923T patent/PT2291380E/pt unknown
- 2009-04-23 WO PCT/EP2009/054882 patent/WO2009130272A1/en not_active Ceased
- 2009-04-23 CN CN2009801142933A patent/CN102066381A/zh active Pending
- 2009-04-23 JP JP2011505510A patent/JP6009764B2/ja not_active Expired - Fee Related
- 2009-04-23 CA CA2722246A patent/CA2722246C/en active Active
- 2009-04-23 DK DK09733923.8T patent/DK2291380T3/da active
- 2009-04-23 AT AT09733923T patent/ATE523512T1/de active
- 2009-04-23 AU AU2009239929A patent/AU2009239929B2/en not_active Ceased
- 2009-04-23 ES ES09733923T patent/ES2373364T3/es active Active
- 2009-04-23 PL PL09733923T patent/PL2291380T3/pl unknown
- 2009-04-23 HR HR20110824T patent/HRP20110824T1/hr unknown
- 2009-04-23 SI SI200930109T patent/SI2291380T1/sl unknown
- 2009-04-23 KR KR1020107025887A patent/KR101598137B1/ko not_active Expired - Fee Related
- 2009-04-23 US US12/937,744 patent/US8440686B2/en not_active Expired - Fee Related
- 2009-04-23 RU RU2010147833/04A patent/RU2495042C2/ru active
- 2009-04-23 RS RS20110534A patent/RS52041B/sr unknown
- 2009-04-23 ME MEP-2011-200A patent/ME01319B/me unknown
2011
- 2011-12-06 CY CY20111101207T patent/CY1112295T1/el unknown

Also Published As

Publication number	Publication date
SI2291380T1 (sl)	2012-01-31
PL2291380T3 (pl)	2012-02-29
US8440686B2 (en)	2013-05-14
RU2010147833A (ru)	2012-05-27
WO2009130272A1 (en)	2009-10-29
JP6009764B2 (ja)	2016-10-19
CN102066381A (zh)	2011-05-18
AU2009239929A1 (en)	2009-10-29
EP2291380B1 (de)	2011-09-07
KR101598137B1 (ko)	2016-02-29
RS52041B (sr)	2012-04-30
KR20110004877A (ko)	2011-01-14
PT2291380E (pt)	2011-12-22
ES2373364T3 (es)	2012-02-02
CA2722246A1 (en)	2009-10-29
US20110034502A1 (en)	2011-02-10
ME01319B (me)	2013-12-20
JP2011518805A (ja)	2011-06-30
DK2291380T3 (da)	2011-12-05
AU2009239929B2 (en)	2014-02-13
HRP20110824T1 (hr)	2012-01-31
CY1112295T1 (el)	2015-12-09
EP2291380A1 (de)	2011-03-09
CA2722246C (en)	2016-06-21
RU2495042C2 (ru)	2013-10-10

Legal Events

Date

Code

Title

Description

2012-05-15

UEP

Publication of translation of european patent specification

Ref document number: 2291380

Country of ref document: EP

Publication	Publication Date	Title
ATE535528T1 (de)	2011-12-15	Nalmefendiesterprodrugs
WO2013163190A8 (en)	2014-11-27	Dna-pk inhibitors
MA33803B1 (fr)	2012-12-03	Inhibiteur de bromodomaine de benzodiazépine
MX353806B (es)	2018-01-30	Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
UA107783C2 (en)	2015-02-25	Isoindoline compounds for use in treating cancer
EA201200473A1 (ru)	2012-10-30	Замещенные (гетероарилметил)тиогидантоины
WO2010008847A3 (en)	2010-10-21	Pi3k/m tor inhibitors
UA108743C2 (uk)	2015-06-10	Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MX340402B (es)	2016-07-07	Inhibidores triciclicos de cinasas.
MY191669A (en)	2022-07-06	Pyrazolyl quinoxaline kinase inihibitors
HK1212348A1 (en)	2016-06-10	Autotaxin inhibitors
WO2011080568A8 (en)	2012-08-23	Novel pyrimidine compounds as mtor and pi3k inhibitors
MY166653A (en)	2018-07-18	Derivatives of 1-amino-2-cyclobutylethylboronic acid
MX349004B (es)	2017-07-06	Nuevos compuestos.
TN2014000016A1 (en)	2015-07-01	4 - piperidinyl compounds for use as tankyrase inhibitors
MX2014013090A (es)	2014-12-08	Derivados de pirrolotriazinona.
UA111198C2 (uk)	2016-04-11	Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
UA107183C2 (uk)	2014-12-10	Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
JO2682B1 (en)	2013-03-03	Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009005938A (es)	2009-06-17	6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
MX2012007341A (es)	2012-07-20	Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
WO2012162513A3 (en)	2013-03-28	Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
CY1112295T1 (el)	2015-12-09	Προφαρμακα ναλμεφενης
WO2011103028A3 (en)	2011-12-08	Compositions and methods for inhibiting mmset
WO2010027458A3 (en)	2010-06-17	Pdk inhibitor compounds and methods of use thereof